The drug, Journavx, from Vertex Pharmaceuticals, reduced pain after surgery in clinical trials. Experts hope it can lead to fewer opioid prescriptions.

D tumoroid models transform cancer research, accurately reflecting tumor biology and enabling effective drug testing and ...

The U.S. Food and Drug Administration said it approved Boston-based Vertex Pharmaceuticals' Journavx for short-term pain that ...

The U.S. Food and Drug Administration (FDA) recently issued two new guidance documents governing details of the Accelerated Approval ...

The FDA clearance aids AstraZeneca and Daiichi Sankyo’s plan to position ADCs like Enhertu ahead of chemotherapy in a variety ...

We recently published a list of 12 Safe Stocks to Buy for the Long Term in 2025. In this article, we are going to take a look ...

At Texas A&M University, one research lab is changing the game of droplet microfluidics, a technique that involves conducting ...

We assign Teva a Morningstar Uncertainty Rating of High, which largely reflects our quantitative analysis of the firm, based on the return ranges used by our star rating system, as well as our ...

Inc. stock despite strong Phase 2b data. Click for my updated look at MNMD stock and its market opportunities.

Scientists have unveiled a groundbreaking method to test how thousands of active substances influence cellular metabolism ...

Inhibition of group IVA cytosolic phospholipase A2 (cPLA2α) is a potential approach for cancer treatment. Here, the authors report thiazolyl ketone inhibitors of cPLA2α starting from compound ...

The savings on the 25 drugs stem from a new law that allows Medicare to haggle over the price it pays on the most popular and expensive prescription drug scripts filled by older Americans.